PROTECT PROJECT

What PROTECT PROJECT does

PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) is a collaborative European research consortium founded in 2009 under the Innovative Medicines Initiative (IMI), a public-private partnership between the European Union and EFPIA. The European Medicines Agency (EMA) serves as coordinator and GlaxoSmithKline (GSK) as deputy coordinator, managing a multi-national consortium of 34 partners spanning academic institutions, regulatory agencies, small and medium enterprises, and EFPIA member pharmaceutical companies. PROTECT's mandate is to address limitations in current methods in pharmacoepidemiology and pharmacovigilance through methodological research rather than commercial product development.

The consortium's core technology centres on pharmacoepidemiological research methods, signal detection methodologies, benefit-risk assessment frameworks, and direct-to-patient data collection systems using web-based, telephone, and text messaging platforms. Work is organised into seven work packages: WP2 (framework and methodological standards for pharmacoepidemiology studies), WP3 (signal detection from spontaneous reports, electronic health records, and clinical trials, including disproportionality analysis, MedDRA term groupings, and duplicate detection), WP4 (direct patient data collection, demonstrated through the PROTECT Pregnancy Study in the UK, Poland, Denmark, and the Netherlands), WP5 (benefit-risk integration with graphical methods including Bayesian modelling and multi-criteria decision analysis), WP6 (replication studies), and WP7 (training and communication). Key outputs include the Adverse Drug Reaction Database, the Drug Consumption Databases inventory covering 29 European countries, and over 100 peer-reviewed publications.

PROTECT does not operate as a commercial entity. Funding flows from the IMI Joint Undertaking (EU and EFPIA contributions), and outputs are disseminated through open-access publications, public databases, and the ENCePP regulatory network free of charge. Beneficiaries include EU and national regulatory agencies, EFPIA member pharmaceutical companies, academic researchers, and patient organizations; healthcare providers and pregnant women participate as data contributors in WP4 studies. The Final Symposium was held in November 2014 as the formal project closure event, and EMA's September 2016 regulatory impact evaluation concluded that PROTECT outputs are being implemented into routine pharmacovigilance and regulatory practice.

Name

PROTECT PROJECT

Legal name

Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium (PROTECT)

Website

https://imi-protect.eu

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

1–10 employees

Short description

PROTECT is a European pharmacoepidemiology research consortium of 34 partners, coordinated by the EMA and funded by the Innovative Medicines Initiative. It develops methodological frameworks, signal detection tools, and patient data collection systems to strengthen medicine safety monitoring.

Ownership category

akta.pro rank

Product category

Pharmacovigilance Research

SIC

Services-Commercial Physical & Biological Research (8731), Services-Testing Laboratories (8734)

akta.pro primary industry

Pharmacovigilance, Safety Signal Management & Risk Minimization (HLAJADAH)

akta.pro secondary industries

Pharmacovigilance, Medication Safety & Controlled Substance Diversion Monitoring (HLAFALAN), Safety Pharmacology (Cardio/CNS/Respiratory) (HLAGAFAB)

Keywords

• Pharmacoepidemiology research
• Pharmacovigilance methods
• Adverse drug reactions
• Signal detection
• Benefit-risk assessment

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Distribution channels1 record

Marketing channels5 records

Core offering

PROTECT is a collaborative European research consortium that develops, tests, and disseminates methodological standards for pharmacoepidemiology and pharmacovigilance. It produces research databases, signal detection frameworks, benefit-risk assessment tools, and direct patient data collection methods, coordinated by the European Medicines Agency (EMA) and supported by 34 public and private partners.

Product overview

PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European Consortium) is a collaborative European research project coordinated by the European Medicines Agency (EMA) with 34 public and private partners. Rather than a commercial product company, PROTECT functions as a research consortium developing innovative tools and methods to strengthen the monitoring of benefit-risk of medicines in Europe. The consortium's offerings consist of research databases (Adverse Drug Reaction Database, Drug Consumption Databases in Europe), methodological frameworks across seven work packages (WP1-WP7) covering pharmacoepidemiology studies, signal detection methods, consumer data collection, benefit-risk assessment, replication studies, and training/communication. Key outputs include databases for adverse drug reactions and drug consumption data, methodological standards for pharmacoepidemiological studies, signal detection methodologies, benefit-risk assessment tools and graphical representations, and the PROTECT Pregnancy Study. These are shared resources for researchers, regulatory agencies, and pharmaceutical companies rather than commercial products.

Differentiator

Problem solved

Functional benefit

Products and services

• Adverse Drug Reaction Database
• Drug Consumption Databases in Europe
• Framework for Pharmacoepidemiology Studies (WP2)
• Methods for Signal Detection (WP3)
• New Methods for Data Collection from Consumers (WP4)
• Benefit-Risk Integration and Representation (WP5)
• PROTECT Pregnancy Study
• Interactive Training Platform

Quantifiable outcome

• Outcomes linked to signal detection and evaluation are being implemented into routine pharmacovigilance and regulatory practice
• +2 more outcomes

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

34 partnerships are on record, tiered core.

• European Medicines Agency (EMA)coreStrategic or Co-development PartnerEMA serves as the coordinator of PROTECT, responsible for overall governance, project management, and integration of outputs into EU regulatory practice. Manages EudraVigilance database and coordinates network of over 4,000 EU experts.
• GlaxoSmithKline (GSK)coreStrategic or Co-development PartnerGSK serves as Deputy Coordinator of PROTECT, coordinating input from private consortium (industry partners). Contributes extensive experience in pharmacovigilance, novel signal detection methodology, and healthcare database expertise.
• Aarhus University (AU)coreStrategic or Co-development PartnerNational Centre for Register-based Research contributes expertise in register-based studies combining genetic and environmental factors. Partners on WP2 Framework for pharmacoepidemiology studies.
• AstraZeneca ABcoreStrategic or Co-development PartnerMajor global pharmaceutical company contributing to WP3 Signal Detection methods. Strong market and R&D presence in cardiovascular, oncology, neuroscience, and respiratory diseases.
• Bayer Pharma AGcoreStrategic or Co-development PartnerContributes to WP3 sub-projects on signal detection properties and clinical trials. Specializes in Diagnostic Imaging, General Medicine, Specialty Medicine and Women's Healthcare with over €10.4 billion in sales.
• Uppsala Monitoring Centre (UMC)coreStrategic or Co-development PartnerWHO Collaborating Centre for International Drug Monitoring, responsible for worldwide collection of ADR reports and management of VigiBase. Leads WP3 sub-projects on MedDRA terminology and signal detection methodology.
• Imperial College LondoncoreStrategic or Co-development PartnerLeads WP5 on Benefit-Risk integration and representation. Internationally recognised expertise in Bayesian statistics and chronic disease epidemiology. Contributes to graphical methods for benefit-risk presentation.
• Universiteit Utrecht (UU)coreStrategic or Co-development PartnerLeading academic group in pharmacoepidemiology, pharmacovigilance and drug innovation. Co-leader of WP2 with expertise in drug utilisation, signal detection, record linkage, and pharmacogenetics.
• Genzyme (Sanofi)coreStrategic or Co-development PartnerBiotechnology company leading WP4 on new methods for data collection from consumers. Conducts pregnancy study using web-based, telephone and text messaging systems.
• Outcome Europe SarlcoreStrategic or Co-development PartnerResearch and technology SME providing studies, registries and technologies for real-world outcomes evaluation. Contributes data collection systems and interoperability standards expertise to WP4.
• LA-SER (PGRx)coreStrategic or Co-development PartnerSME providing PGRx pharmacoepidemiologic system for assessment of risks and benefits of medicines. Leads WP6 on replication studies involving Extended Audience.
• RochecoreStrategic or Co-development PartnerLeading research-focused healthcare group in pharmaceuticals and diagnostics. Contributes to WP3 sub-project on drug-drug interaction signal detection in spontaneous reports databases.
• PfizercoreStrategic or Co-development PartnerWorld's largest research-based pharmaceutical company. Co-leader of WP2 with experience in risk management, pharmacovigilance, and signal detection within integrated safety division.
• Novartis Pharma AGcoreStrategic or Co-development PartnerMultinational pharmaceutical company with expertise in discovering and developing innovative products. Contributes to WP7 Training and Communication and WP5 Benefit-Risk assessment.
• Novo Nordisk A/ScoreStrategic or Co-development PartnerHealthcare company and world leader in diabetes care. Contributes to WP5 Benefit-Risk case studies including Warfarin and Natalizumab assessments.
• Sanofi-AventiscoreStrategic or Co-development PartnerAmong worldwide top three major pharmaceutical companies. Contributes to WP1 project management and WP6 replication studies.
• Merck KGaA (Merck Serono)coreStrategic or Co-development PartnerGlobal pharmaceutical and chemical group with €1bn annual R&D expenditure. Contributes to WP3 structured database of SPC adverse events and WP5 Benefit-Risk assessment.
• TakedacoreStrategic or Co-development PartnerOldest and largest pharmaceutical company in Japan with EU operations. Contributes to WP6 replication studies with expertise in CNS, oncology, and gastroenterological diseases.
• Eli LillycoreStrategic or Co-development PartnerLeading innovation-driven corporation developing pharmaceutical products through worldwide laboratories. Contributes to WP2 and WP3 pharmacoepidemiology methodologies.
• Amgen NVcoreStrategic or Co-development PartnerBiotechnology pioneer since 1980, delivering innovative human therapeutics. Contributes to WP4 pregnancy study data collection methods.
• Medicines and Healthcare products Regulatory Agency (MHRA)coreStrategic or Co-development PartnerUK regulatory agency for medicines and medical devices. Operates GPRD database (world's largest computerized primary care database) and leads WP3 sub-projects on duplicate detection.
• Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)coreStrategic or Co-development PartnerSpanish Medicines Agency operating BIFAP database (2.2 million patients). Leads WP3 sub-projects on disproportionality statistics and concordance studies.
• Lægemiddelstyrelsen (Danish Medicines Agency)coreStrategic or Co-development PartnerDanish regulatory agency with Register of Medicinal Product Statistics covering total medicine sales from 1994. Contributes to WP1 management and WP3 signal detection recommendations.
• Institut National de la Santé et de la Recherche Médicale (INSERM)coreStrategic or Co-development PartnerFrench research institute developing knowledge-based systems in medicine. Leads WP3 sub-project on automatic generation of MedDRA terms groupings using ontology (OntoADR).
• Ludwig-Maximilians-Universität München (LMU)coreStrategic or Co-development PartnerGerman university with Department for Medical Informatics, Biometry and Epidemiology. Develops regional pharmacovigilance centers concept and contributes to WP2 and WP3.
• Mario Negri Institute for Pharmacological ResearchcoreStrategic or Co-development Partner45-year old not-for-profit biomedical research organisation with 900 employees. Contributes to WP5 benefit-risk assessment with expertise in drug safety research.
• International Alliance of Patients' Organizations (IAPO)coreStrategic or Co-development PartnerPatient-led alliance of 200 member organisations representing 365 million patients worldwide. Contributes to WP4 pregnancy study and WP7 training dissemination.
• Poznan University of Medical Sciences (PUMS)coreStrategic or Co-development PartnerLeading Polish medical centre with Polish Registry of Congenital Malformations (400,000+ births/year). EUROCAT full member. Contributes to WP4 pregnancy study.
• Rijksuniversiteit Groningen (University of Groningen)coreStrategic or Co-development PartnerUnit of Pharmacoepidemiology & Pharmacoeconomics focuses on benefit-risk profiles, drug prescribing studies, and reproductive pharmacovigilance. Collaborates with EUROCAT network.
• University of Newcastle upon TynecoreStrategic or Co-development PartnerHosts UK National Teratology Information Service, part of European Network of Teratology Information Services (ENTIS). Contributes expertise in birth defects prevention to WP4.
• Witten/Herdecke UniversitycoreStrategic or Co-development PartnerGerman model university developing potentially inappropriate medication lists for elderly patients. Contributes to medication errors and nursing home research.
• Fundació Institut Català de Farmacologia (FICF)coreStrategic or Co-development PartnerCatalan Institute of Pharmacology designs and coordinates pharmacoepidemiology studies. Leads WP7 on training and communication with expertise in voluntary reporting schemes.
• Fundación CEIFEcoreStrategic or Co-development PartnerSpanish Centre for Pharmacoepidemiologic Research using GPRD, THIN, BIFAP and Saskatchewan databases. Contributes expertise in drug safety and effectiveness studies.
• H. Lundbeck A/ScoreStrategic or Co-development PartnerInternational pharmaceutical company focused on psychiatric and neurological disorders. Contributes pharmacovigilance and pharmacoepidemiology expertise using healthcare databases.

Scale indicators7 records

Recent moves5 records

Expansion highlights4 records

Broad incumbents

• Innovative Health Initiative (IHI): Successor to the Innovative Medicines Initiative (IMI), the funder of PROTECT. Comparable as the overarching public-private partnership funding mechanism for European cross-stakeholder health research consortia.
• Sentinel Initiative: US FDA's national pharmacovigilance and active surveillance system using electronic health data. Comparable in mission (medicine safety monitoring, signal detection, benefit-risk assessment) but US-focused and operated as a federal initiative.

Others

• International Society for Pharmacoepidemiology (ISPE): Global scientific/professional society for pharmacoepidemiology. Comparable as the community host for ICPE, the principal dissemination venue for PROTECT outputs, and as a steward of pharmacoepidemiology methodological standards.

Emerging players

• Clinical Practice Research Datalink (CPRD): UK-based primary care research datalink (formerly GPRD, a key data source for PROTECT's WP2 work). Comparable as a real-world data infrastructure underpinning pharmacoepidemiology research PROTECT methods relied on.
• VAC4EU: European vaccine benefit-risk monitoring consortium. Comparable given its overlapping mission on benefit-risk assessment methods, real-world data harmonization, and signal detection for medicinal products, in a complementary therapeutic area.

Direct peers

• EU-ADR Alliance: FP7-funded European predecessor project to PROTECT developing ADR signal detection from EHR data. Tightly comparable as a European public-private research consortium focused on harmonized methods for adverse drug reaction detection.
• European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP): EMA-coordinated network of research centres in pharmacoepidemiology and pharmacovigilance. Directly comparable because PROTECT outputs are explicitly disseminated through ENCePP, and both operate as EMA-anchored EU pharmacovigilance research infrastructures.
• OHDSI (Observational Health Data Sciences and Informatics): Global multi-stakeholder collaborative developing open-source methods for large-scale health data analytics and signal detection. Directly comparable to PROTECT in tackling pharmacoepidemiology method standardization across heterogeneous real-world data sources.
• WHO Uppsala Monitoring Centre (UMC) / VigiBase: WHO Collaborating Centre operating VigiBase, the world's largest ADR spontaneous reports database. Directly comparable as PROTECT partners (UMC led WP3 MedDRA terminology and signal detection sub-projects), aligning on pharmacovigilance signal management.
• EHDEN (European Health Data & Evidence Network): IMI-funded federated network harmonizing European health data for outcomes research. Direct peer given shared IMI funding lineage, European scope, and overlapping focus on pharmacoepidemiology and real-world evidence methodologies.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/protect-project

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PROTECT PROJECT